CANbridge Pharmaceuticals Receives Marketing Approval for Nerlynx® (Neratinib) in China
May 14, 2020
CANbridge Pharmaceuticals Completes US$98 Million Series D Financing
Feb 19, 2020
Shanghai Foundation for Rare Disease Appoints CANbridge CEO, James Xue, Deputy Director General Sole Representative from the Pharmaceutical Industry
Jan 06, 2020